Article ; Online: Gene therapy for neuromuscular disorders: prospects and ethics.
Archives of disease in childhood
2021 Volume 107, Issue 5, Page(s) 421–426
Abstract: Most childhood neuromuscular disorders are caused by mutations causing abnormal expression or regulation of single genes or genetic pathways. The potential for gene therapy, gene editing and genetic therapies to ameliorate the course of these conditions ... ...
Abstract | Most childhood neuromuscular disorders are caused by mutations causing abnormal expression or regulation of single genes or genetic pathways. The potential for gene therapy, gene editing and genetic therapies to ameliorate the course of these conditions is extraordinarily exciting, but there are significant challenges associated with their use, particularly with respect to safety, efficacy, cost and equity. Engagement with these novel technologies mandates careful assessment of the benefits and burdens of treatment for the patient, their family and their society. The examples provided by spinal muscular atrophy and Duchenne muscular dystrophy illustrate the potential value and challenges of gene and genetic therapies for paediatric neurological conditions. The cost and complexity of administration of these agents is a challenge for all countries. Jurisdictional variations in availability of newborn screening, genetic diagnostics, drug approval and reimbursement pathways, treatment and rehabilitation will affect equity of access, nationally and internationally. These challenges will best be addressed by collaboration by governments, pharma, clinicians and patient groups to establish frameworks for safe and cost-effective use of these exciting new therapies. |
---|---|
MeSH term(s) | Child ; Genetic Therapy/methods ; Humans ; Infant, Newborn ; Muscular Atrophy, Spinal/genetics ; Muscular Atrophy, Spinal/therapy ; Muscular Dystrophy, Duchenne/diagnosis ; Muscular Dystrophy, Duchenne/genetics ; Muscular Dystrophy, Duchenne/therapy ; Neonatal Screening ; Neuromuscular Diseases/diagnosis ; Neuromuscular Diseases/genetics ; Neuromuscular Diseases/therapy |
Language | English |
Publishing date | 2021-08-30 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 524-1 |
ISSN | 1468-2044 ; 0003-9888 ; 1359-2998 |
ISSN (online) | 1468-2044 |
ISSN | 0003-9888 ; 1359-2998 |
DOI | 10.1136/archdischild-2020-320908 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Um IV Zs.106: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MA 3: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.